Clinical Trials Logo

Histiocytic Disorders, Malignant clinical trials

View clinical trials related to Histiocytic Disorders, Malignant.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04079179 Recruiting - Clinical trials for Neuro-Degenerative Disease

Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

NACHO-COBI
Start date: April 19, 2021
Phase: Phase 2
Study type: Interventional

This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment. Cobimetinib blocks activation of a protein called Mitogen-activated protein kinase (MEK) that is part of incorrect growth signals in histiocytosis cells. Four different groups of patients will be enrolled.